Clinical efficacy of desloratadine in chronic urticaria

Clinical Drug Investigation

Volumn 22, Issue SUPPL. 2, 2002, Pages 33-41

  Ring, Johannes ^a   Gauger, Anke ^a   Hein, Rüdiger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; DESLORATADINE; HISTAMINE H1 RECEPTOR; PLACEBO; SEROTONIN 1 ANTAGONIST;

ALLERGIC REACTION; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER; SYMPTOMATOLOGY;

EID: 0036328934     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222002-00004     Document Type: Review

References (32)

1. Chronic urticaria
2. Antihistamines in urticaria
3. Chronic urticaria
4. The impact of chronic urticaria on the quality of life
5. 2-antagonists in allergic and pseudoallergic diseases
6. Histamine and allergic diseases
7. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria
8. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria
9. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria
10. Anti-FcεRI auto-antibodies and basophil histamine releasability in chronic idiopathic urticaria
11. Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine
12. 1 receptors
13. 1 receptor [abstract 526]
14. 1-antagonist, desethoxycarbonyl-loratadine
15. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc ε RI+ cells
16. The pathogenesis of chronic idiopathic urticaria
17. Allergy and hypersensitivity
18. Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria
19. Urticaria: New developments and perspectives
20. Binding and antiallergic characteristics of desloratadine
21. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines
22. Inhibition of cytokine generation and mediator release in human basophils by desloratadine
23. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells
24. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells
25. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation
26. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines
27. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: Results of the MILOR Study
28. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria
29. A randomised, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers
30. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomised, double-blind, placebo-controlled study